Prediction of obstetrical risk using maternal serum markers and clinical risk factors

Metcalfe, Amy; Langlois, Sylvie; MacFarlane, Julie; Vallance, Hilary; Joseph, K. S.

doi:10.1002/pd.4281

Cited by 23 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metcalfe et al (7) reported that biomarkers currently used to screen for aneuploidy have detection rates too low to identify women at risk for adverse obstetrical outcomes. Menon et al (36) reviewed 116 different biomarkers assayed 578 times in 217 studies, and found that no single biomarker could reliably predict PTB.…”

Section: Discussionmentioning

confidence: 99%

Changes in antimüllerian hormone levels in early pregnancy are associated with preterm birth

Stegmann¹,

Santillan

Leader³

et al. 2015

Fertility and Sterility

View full text Add to dashboard Cite

Objective To determine the association of preterm birth with anti-Mullerian hormone (AMH) levels, both in isolation and in combination with other markers of feto-placental health commonly measured during Integrated Prenatal Screening (IPS) for aneuploidy. Design Retrospective case-control study Setting State of Iowa Patients All pregnant women in Iowa who elected to undergo IPS and who subsequently delivered in Iowa were eligible for inclusion. Cases included women giving birth at <37 weeks gestation, controls included those who delivered at ≥37 weeks gestation. Interventions none Main outcome measure(s) Probability of a preterm birth Results 2nd trimester AMH levels were not associated with preterm birth, either independently or after controlling for other markers of feto-placental health. AMH difference was not associated with preterm birth when modeled alone, but a statistically significant association was found after adjusting for maternal serum alpha-fetoprotein (MSAFP) and maternal weight change between the 1st and 2nd trimester. After stratifying the model by MSAFP level, most of the risk for preterm birth was identified in women with an MSAFP >1 Multiple of the Median (MoM) and who had a stable or rising AMH level in early pregnancy. Conclusions A lack of decline in the AMH level in early pregnancy can be used to identify women with a high probability for preterm birth, especially when MSAFP levels are >1 MoM. Monitoring changes in the AMH level between the 1st and 2nd trimesters of pregnancy may help identify women who would benefit from interventional therapies such as supplemental progesterone.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in antimüllerian hormone levels in early pregnancy are associated with preterm birth

Stegmann¹,

Santillan

Leader³

et al. 2015

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Although several prediction models for PE have been reported to date, [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] they require data from examinations (blood test and/or Doppler velocimetry) and complex questionnaires on maternal background. The present study was conducted in order to determine predictive risk factors for GH and PE in Japan, develop a nomogram for calculating estimated risk ratios of GH and PE, and identify high-risk women in prenatal visits.…”

Section: Introductionmentioning

confidence: 99%

Prenatal risk assessment of gestational hypertension and preeclampsia using clinical information

Shiozaki

Tanaka

Ito

et al. 2016

Hypertens Res Pregnancy

View full text Add to dashboard Cite

Aim:To assess the risks of developing gestational hypertension (GH) and preeclampsia (PE) during pregnancy based on clinical information. ). The estimated risk ratios predicted subsequent GH and PE with sensitivities of 61.5% and 67.0%, and specificities of 67.0% and 64.4%, respectively. The areas under the receiver operating characteristic curves for GH and PE were 0.70 and 0.68, respectively. Conclusions:The estimated risk ratios determined in this study may identify women at high risk of GH or PE before disease onset.

show abstract

“…race and obesity) and blood pressure. The list of such markers includes pregnancy associated plasma protein A, placental growth factor, placental protein‐13, and ADAM‐12 . Studies published in 2013 have validated the predictive ability of such markers identified in previous small‐scale discovery studies.…”

Section: The Use Of Serum Analytes To Determine Fetal Well‐beingmentioning

confidence: 99%

In case you missed it: thePrenatal Diagnosissection editors bring you the most significant advances of 2013

Bianchi

Mieghem

Shaffer³

et al. 2014

Prenat Diagn

View full text Add to dashboard Cite

Prediction of obstetrical risk using maternal serum markers and clinical risk factors

Abstract: While detection rates are low, the combination of maternal serum markers and obstetrical history helps to identify a small subset of women at higher risk for serious perinatal events and severe pre-eclampsia.

Cited by 23 publications

References 26 publications

Changes in antimüllerian hormone levels in early pregnancy are associated with preterm birth

Changes in antimüllerian hormone levels in early pregnancy are associated with preterm birth

Prenatal risk assessment of gestational hypertension and preeclampsia using clinical information

In case you missed it: thePrenatal Diagnosissection editors bring you the most significant advances of 2013

Contact Info

Product

Resources

About